Concepedia

Publication | Closed Access

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

DOI

210

Citations

41

References

2007

Year

David B. Solit, S. Percy Ivy, Catherine Kopil, Rachel Sikorski, Michael J. Morris, Susan F. Slovin, William K. Kelly, A. Delacruz, Tracy Curley, Glenn Heller,
Clinical Cancer Research

Abstract

The MTD and toxicity profile of 17-AAG were schedule dependent. Intermittent dosing schedules were less toxic and are recommended for future phase II studies.

References

YearCitations

Page 1